Free Trial

ZimVie (ZIMV) Competitors

ZimVie logo
$18.90 +0.02 (+0.11%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$18.90 0.00 (0.00%)
As of 09/23/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZIMV vs. LMAT, PRCT, AORT, EYE, ENOV, CNMD, NVCR, CDRE, BLFS, and BBNX

Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), Cadre (CDRE), BioLife Solutions (BLFS), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

ZimVie vs. Its Competitors

ZimVie (NASDAQ:ZIMV) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

LeMaitre Vascular has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZimVie$449.75M1.19-$25.83M-$0.70-27.00
LeMaitre Vascular$234.64M8.67$44.04M$2.0643.63

In the previous week, LeMaitre Vascular had 4 more articles in the media than ZimVie. MarketBeat recorded 5 mentions for LeMaitre Vascular and 1 mentions for ZimVie. LeMaitre Vascular's average media sentiment score of 1.63 beat ZimVie's score of 1.17 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ZimVie
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LeMaitre Vascular
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

ZimVie currently has a consensus target price of $17.75, suggesting a potential downside of 6.08%. LeMaitre Vascular has a consensus target price of $97.60, suggesting a potential upside of 8.60%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than ZimVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZimVie
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
LeMaitre Vascular
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

LeMaitre Vascular has a net margin of 20.08% compared to ZimVie's net margin of -4.39%. LeMaitre Vascular's return on equity of 13.67% beat ZimVie's return on equity.

Company Net Margins Return on Equity Return on Assets
ZimVie-4.39% 6.37% 3.34%
LeMaitre Vascular 20.08%13.67%9.14%

ZimVie has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

95.6% of ZimVie shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 5.4% of ZimVie shares are owned by company insiders. Comparatively, 9.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LeMaitre Vascular beats ZimVie on 13 of the 16 factors compared between the two stocks.

Get ZimVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZIMV vs. The Competition

MetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$532.62M$10.70B$5.76B$10.50B
Dividend YieldN/A1.90%5.53%4.57%
P/E Ratio-27.0020.5975.9626.62
Price / Sales1.1938.02473.7891.77
Price / Cash10.1624.5937.4661.85
Price / Book1.373.4013.486.45
Net Income-$25.83M$212.47M$3.29B$271.57M
7 Day Performance0.11%0.14%1.83%2.61%
1 Month Performance-0.26%-2.71%4.00%7.28%
1 Year Performance18.79%-10.38%75.89%29.60%

ZimVie Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIMV
ZimVie
1.1762 of 5 stars
$18.90
+0.1%
$17.75
-6.1%
+18.3%$532.62M$449.75M-27.001,770Positive News
LMAT
LeMaitre Vascular
3.2754 of 5 stars
$92.37
+0.1%
$97.60
+5.7%
-1.7%$2.09B$219.86M44.84490Positive News
Analyst Forecast
PRCT
PROCEPT BioRobotics
2.7764 of 5 stars
$38.00
+2.3%
$70.00
+84.2%
-51.2%$2.07B$224.50M-24.52430Positive News
AORT
Artivion
2.5696 of 5 stars
$39.74
-2.4%
$40.63
+2.2%
+62.5%$1.92B$388.54M-94.621,600Positive News
EYE
National Vision
2.2151 of 5 stars
$23.61
+2.7%
$24.73
+4.7%
+157.6%$1.82B$1.82B-131.1713,411
ENOV
Enovis
3.9439 of 5 stars
$32.35
+2.0%
$51.00
+57.7%
-28.4%$1.81B$2.11B-2.277,367Positive News
CNMD
CONMED
4.5738 of 5 stars
$51.76
-2.1%
$59.80
+15.5%
-35.6%$1.64B$1.33B14.663,900
NVCR
NovoCure
4.3164 of 5 stars
$12.72
+4.7%
$28.79
+126.3%
-21.4%$1.36B$630.16M-8.151,488Positive News
CDRE
Cadre
2.2145 of 5 stars
$32.72
+0.6%
$31.50
-3.7%
-0.8%$1.32B$567.56M34.812,284Positive News
BLFS
BioLife Solutions
2.9966 of 5 stars
$25.80
+1.1%
$31.29
+21.3%
-0.2%$1.22B$82.25M-214.98440Positive News
BBNX
Beta Bionics
1.1153 of 5 stars
$25.31
-4.2%
$22.56
-10.9%
N/A$1.15B$65.12M0.00294Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ZIMV) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners